Ignite Creation Date:
2024-05-06 @ 2:59 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04489888
Status:
COMPLETED
Last Update Posted:
2024-05-09
First Post:
2020-07-27
Brief Title:
A Study of Pembrolizumab MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of RecurrentMetastatic Head and Neck Squamous Cell Carcinoma MK-3475-B10KEYNOTE B10
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase 4 Single-arm Open-label Clinical Study of Pembrolizumab MK-3475 to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of RecurrentMetastatic Head and Neck Squamous Cell Carcinoma KEYNOTE B10
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrentmetastatic head and neck squamous cell carcinoma RM HNSCC No statistical hypothesis will be tested in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3475-B10 | OTHER | Merck | None |